Acetyl-L-Carnitine Augmentation of Clozapine in Partial-Responder Schizophrenia: A 12-Week, Open-Label Uncontrolled Preliminary Study

被引:19
|
作者
Bruno, Antonio [1 ]
Pandolfo, Gianluca [1 ]
Crucitti, Manuela [1 ]
Lorusso, Simona [1 ]
Zoccali, Rocco Antonio [1 ]
Muscatello, Maria Rosaria Anna [1 ]
机构
[1] Univ Messina, Psychiat Unit, Dept Biomed & Dent Sci & Morphofunct Imaging, Polyclin Hosp Univ Via Consolare Valeria, I-98125 Messina, Italy
关键词
acetyl-L-carnitine; schizophrenia; clozapine; augmentation; TREATMENT-RESISTANT SCHIZOPHRENIA; DOUBLE-BLIND; ALZHEIMERS-DISEASE; METAANALYSIS; TRIALS; DEPRESSION; METABOLISM; EFFICACY; PLACEBO;
D O I
10.1097/WNF.0000000000000170
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: This was the first 12-week, open-label, uncontrolled trial aimed at exploring the efficacy of acetyl-L-carnitine (ALC) add-on pharmacotherapy on clinical symptoms and cognitive functioning in 15 schizophrenia patients with suboptimal clinical response despite receiving clozapine (CLZ) monotherapy at the highest tolerated dosage. Methods: After clinical (Positive and Negative Symptoms Scale [PANSS]) and neuropsychological (Wisconsin Card Sorting Test, Stroop Color-Word Test, Verbal Fluency Test) assessments, patients received 1 g/d of ALC for 12 weeks. Results: A final sample of 9 subjects completed the study. Acetyl-L-carnitine augmentation of CLZ significantly reduced only PANSS domains "positive" (P = 0.049); at end point, only 2 subjects (22.2% of the completers) reached a minimal improvement (25% reduction in PANSS total score). No significant differences emerged in cognitive performances at the end of the study; effect sizes were small in each explored cognitive dimension. Conclusions: The findings provide preliminary evidence that ALC added to ongoing CLZ treatment appeared to be ineffective to improve symptoms in schizophrenia patientswho have failed to respond sufficiently to CLZ. Further trials with adequately powered methodology are needed to identify which augmentation strategies are more effective in schizophrenia patients showing a suboptimal response to CLZ.
引用
收藏
页码:277 / 280
页数:4
相关论文
共 50 条
  • [31] Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea - A 12-week, open-label study
    Schwartz, JRL
    Hirshkowitz, M
    Erman, MK
    Schmidt-Nowara, W
    CHEST, 2003, 124 (06) : 2192 - 2199
  • [32] A 12-WEEK OPEN-LABEL EXTENSION STUDY TO ASSESS THE EFFICACY AND SAFETY OF COMBINATION OF TOLTERODINE AND PILOCARPINE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER AFTER 12-WEEK RANDOMIZED CONTROLLED STUDY
    Lee, K.
    Ko, K. J.
    Lee, J. Z.
    Oh, S.
    Kim, H. G.
    Min, K. S.
    Hong, J. Y.
    Noh, J. H.
    NEUROUROLOGY AND URODYNAMICS, 2017, 36 : S422 - S423
  • [33] LURASIDONE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER WITH MIXED FEATURES: RESULTS OF A 12-WEEK OPEN-LABEL EXTENSION STUDY
    Stahl, S. M.
    Pikalov, A.
    Tocco, M.
    Mao, Y.
    Loebel, A.
    Hopwood, M.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 145 - 146
  • [34] Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study
    Chen, Jun
    Muzina, David J.
    Kemp, David E.
    Conroy, Carla
    Chan, Philip
    Serrano, Mary Beth
    Ganocy, Stephen J.
    Fang, Yiru
    Calabrese, Joseph R.
    Gao, Keming
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (08) : 588 - 595
  • [35] Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study
    Mitsonis, Charalampos I.
    Dimopoulos, Nikolaos P.
    Mitropoulos, Panagiotis A.
    Kararizou, Evangelia G.
    Katsa, Alexandra N.
    Tsakiris, Fivos E.
    Katsanou, Maria Nefeli E.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (02): : 373 - 377
  • [36] Effects of atorvastatin 10 mg/d on insulin resistance:: A 12-week, open-label study in hyperlipidemic patients
    Özerkan, F
    Özdogan, B
    Zoghi, M
    Nalbantgil, S
    Yavuzgil, O
    Önder, MR
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2006, 67 (01): : 44 - 54
  • [37] Switching from other second generation antipsychotics to zotepine in schizophrenic patients: an 12-week open-label study
    Chen, J. Y.
    Chen, T. T.
    Lin, C. C.
    Bai, Y. M.
    Wu, B. J.
    Hung, C. H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S416 - S417
  • [38] Efficacy and tolerability of carbamazepine for the treatment of painful diabetic neuropathy in adults: a 12-week, open-label, multicenter study
    Saeed, Tariq
    Nasrullah, Muhammad
    Ghafoor, Adnan
    Shahid, Riaz
    Islam, Nadeem
    Khattak, Mohammad Usman
    Maheshwary, Neeta
    Siddiqi, Ahson
    Khan, Muhammad Athar
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2014, 7 : 339 - 343
  • [39] Lurasidone for the treatment of major depressive disorder with mixed features: results of a 12-week open-label extension study
    Stahl, S. M.
    Pikalov, A.
    Tocco, M.
    Mao, Y.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2019, 56 : S94 - S94
  • [40] Safety and efficacy of long-acting risperidone in schizophrenia: A 12-week open-label study in stable patients switched from oral antipsychotic treatment
    Lindenmayer, J
    Eerdekens, E
    Berry, S
    Eerdekens, M
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 173 - 173